Home > Oncology > ASCO GU 2022 > Prostate Cancer > Artificial intelligence improves prediction of long-term outcomes

Artificial intelligence improves prediction of long-term outcomes

Presented By
Dr Osama Mohamad, University of California San Francisco, CA, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
An artificial intelligence (AI) tool, trained on data from 5 randomised-controlled trials, proved to be more effective than clinical prognostic markers for predicting long-term outcomes in patients with prostate cancer. To risk stratify patients, most guidelines, including the NCCN guidelines, use parameters like prostate-specific antigen (PSA), digital rectal exam (DRE), and Gleason score. However, this risk stratification tool is suboptimal in terms of performance. More recently, tissue assays have been developed assessing genomic biomarkers, but they are expensive and slow. AI tools leveraging digital pathology may provide solutions to these problems because they are quick, robust, and can be developed on thousands of patient samples without consuming any tissue. Dr Osama Mohamad (University of California San Francisco, CA, USA) presented a prognostic AI tool that was trained and validated using data from 5 phase 3 randomised trials, by leveraging mult...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on